In the United States, four out of ten people will have cancer in their lifetimes. [1] Worldwide, the figures are a little better, “about 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease.” As the American Cancer Society notes, lifestyle, environmental factors and family history can...
Read More
In a nutshell This study reported the long-term effectiveness and safety of the fixed-duration combination of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva)–based immunochemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The data showed that a fixed-duration combination of ibrutinib plus obinutuzumab-based...
Read More
In a nutshell This study evaluated the effectiveness of decitabine (Dacogen) combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of patients with recurrent and refractory (r/r) acute myeloid leukemia (AML). The data showed that decitabine combined with allo-HSCT reduced the risk of recurrence and improved...
Read More
In a nutshell This study evaluated the effectiveness of oral azacitidine (Onureg; Oral-AZA) maintenance treatment in older patients with acute myeloid leukemia (AML) in remission. The data showed that Oral-AZA maintenance therapy can be considered in older patients with AML for which hematopoietic stem cell transplantation (HSCT) is not an...
Read More
In a nutshell This study compared the effectiveness of treatment with all-trans retinoic acid (ATRA; Retin-a) and arsenic trioxide (ATO; Trisenox) to ATRA-ATO with chemotherapy (CHT) in patients with newly diagnosed acute promyelocytic leukemia (APL). The data showed that treatment with ATRA-ATO was equally effective as ATRA-ATO plus CHT in these...
Read More
In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...
Read More
In a nutshell This study compared the effectiveness and safety of low-dose (LD) cytarabine (Ara-C; Cytosar-U) with recombinant arginase BCT-100 (BCT-100) to Ara-C alone in older patients with acute myeloid leukemia (AML) that were unsuitable for intensive therapy. The data showed that LD Ara-C (LDAC) combined with BCT-100 resulted in similar...
Read More
In a nutshell This study analyzed the effect of inotuzumab ozogamicin (InO; Besponsa) treatment on time to subsequent salvage therapy (TST) in patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL). The data showed that TST was longer with InO compared to standard of care (SoC) treatment. Some background Salvage...
Read More
In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor...
Read More
In a nutshell This study investigated the effectiveness and safety of gilteritinib (Xospata) plus azacitidine (Vidaza) versus azacitidine alone for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The data showed that gilteritinib plus azacitidine...
Read More
In a nutshell This study analyzed the use of allogeneic hematopoietic stem cell transplantation (alloHSCT) therapy following first remission in children with newly diagnosed, high-risk acute myeloid leukemia (AML) compared to chemotherapy. This study supports the use of alloHSCT for children with AML that are at greater. Some background Childhood AML...
Read More
